Trials / Completed
CompletedNCT00301964
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Bevacizumab (NCI-Supplied Agent: NSC# 704865, IND # 7921) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase II trial is studying how well bevacizumab works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.
Detailed description
PRIMARY OBJECTIVES: I. Assess the activity of bevacizumab, in terms of 6-month progression-free survival rate and objective tumor response, in patients with recurrent or persistent endometrial cancer. II. Determine the nature and degree of toxicity of bevacizumab in these patients. SECONDARY OBJECTIVES: I. Determine the duration of progression-free survival and overall survival of these patients. II. Determine the effects of prognostic factors, including performance status and histological grade. OUTLINE: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | bevacizumab | Given IV |
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2006-03-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2006-03-13
- Last updated
- 2019-07-24
- Results posted
- 2014-11-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00301964. Inclusion in this directory is not an endorsement.